CXCR1 and lung cancer: In a recent study, Horn et al. demonstrated improved immune response and prognostically favorable TME remodeling of breast and lung cancer in a murine model after simultaneous inhibition of the CXCR1/2 and TGF-ß pathway during PDL-1 therapy [112].